Literature DB >> 23076668

[Current aspects of diagnostics of hepatic dysfunction in critically ill].

F Gonnert1, M Bauer, A Kortgen.   

Abstract

Hepatic dysfunction may develop in critically ill patients in the course of extrahepatic diseases such as sepsis and is frequently limiting prognosis. Conventional "static" laboratory parameters assess hepatocellular damage, synthetic function or cholestasis, providing informations about (differential) diagnostic aspects, while their significance to assess rapid changes in flow and function in the critical care setting is limited. In contrast, quantitative (or "dynamic") liver function tests, such as measurement of plasma disappearance rate of indocyanine green (PDRICG) or 13C-methacetin metabolism, assess specific metabolic and/or excretory function of the liver together with sinusoidal perfusion at the time of measurement and can detect liver dysfunction early in the course of critical illness. In addition, PDRICG demonstrated prognostic significance, albeit, severity of canalicular excretory dysfunction might be underestimated. For chronic liver disease, scoring systems, such as the Child-Turcotte-Pugh-score or the MELD, were developed to assess severity of disease and probability of survival. Scoring systems are also used for graft allocation. Combining scoring systems with dynamic tests holds the potential to improve predictive value, e.g. in the transplant setting. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23076668     DOI: 10.1055/s-0032-1327192

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

Review 1.  The role of the liver in sepsis.

Authors:  Jun Yan; Song Li; Shulin Li
Journal:  Int Rev Immunol       Date:  2014-03-10       Impact factor: 5.311

Review 2.  [Monitoring of liver function in the critically ill].

Authors:  C Sponholz; F A Gonnert; A Kortgen; M Bauer
Journal:  Anaesthesist       Date:  2014-07       Impact factor: 1.041

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.